Blog

DEEP RESEARCH · HIMS & HERS HEALTH

Hims & Hers Health Deep Dive: Is It Becoming the Amazon of Healthcare?

A review of the DTC subscription model, nearly 2.5 million subscribers, GLP-1 pivot, and regulatory risk.

Published: 2025-11-07 · Digital healthcare platform analysis · Naver Blog

Investment decisions are your own responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

My core view is that HIMS has moved from a generic subscription business for hair loss and sexual health into a vertically integrated healthcare platform with nearly 2.5 million subscribers. 3Q25 revenue grew 49% year over year to $599 million, and full-year guidance points to more than $2.3 billion of revenue and a 13% adjusted EBITDA margin.

HIMS platform shiftFrom DTC subscription to chronic-care and prevention ecosystem
Starting wedgeHair loss, ED, stigma categories
ExpansionWomen’s health, mental health, dermatology, weight loss
Revenue engine90%+ subscription revenue and personalization
Next layersLongevity, testosterone, cancer screening, international
The question is whether platform growth can outweigh GLP-1 regulation and margin volatility.

1. Business model: vertically integrated friction removal

Official fact: HIMS was founded in 2017 around areas men often avoid discussing in person, such as hair loss and sexual health, and built a DTC telehealth model spanning diagnosis, prescription, fulfillment, and delivery.

Interpretation: The early success was less about a medical breakthrough and more about access, price, privacy, and convenient recurring delivery. The same customer relationship was then expanded into women’s health, mental health, dermatology, and weight management.

Lock-in

90%+ subscription revenue

Recurring revenue lowers volatility and makes the revenue base more predictable.

Retention

82% at 3 months, 85% long term

The source treats retention as key evidence of platform stickiness.

Personalization

60%+ of subscribers

More than 60% of subscribers use personalized treatment plans.

Integration

Care to delivery

Vertical integration supports cost control and customer experience.

2. 2025 results: EBITDA strength matters more than EPS optics

3Q25 revenue was $599 million, up 49% year over year. Gross margin was 79%, net income was $75.6 million, diluted EPS was $0.32, and adjusted EBITDA was $78.4 million. Full-year 2025 guidance calls for more than $2.3 billion in revenue, $307 million to $317 million of adjusted EBITDA, and a 13% adjusted EBITDA margin.

Item3Q25Read-through
Revenue$599M, YoY +49%Weight-loss and category expansion
Gross margin79%High-margin digital subscription structure
Net income$75.6MCompare carefully against prior-year tax benefit
Adjusted EBITDA$78.4MUnderlying profit power increased 53%
Full-year guidance$2.3B+ revenue, 13% EBITDA marginGrowth and profitability target together

Interpretation: The apparent 81.3% year-over-year EPS decline is heavily affected by the $60.8 million one-time tax benefit in 3Q24. I would focus more on revenue growth and adjusted EBITDA than on the headline EPS comparison.

3. GLP-1 strategy: risk became a platform test

Official fact: The 2024-2025 growth cycle was tied to the GLP-1 weight-loss market, while FDA scrutiny of compounded GLP-1 products was a major risk. The source frames that pressure as a trigger for HIMS to pivot toward branded distribution, including Wegovy-related partnership moves with Novo Nordisk.

Interpretation: The key question is whether HIMS is merely selling cheaper substitutes or whether it can act as an efficient distribution platform for branded pharmaceutical products. The Novo Nordisk partnership, negotiations, and termination headlines all test that platform role and the regulatory sensitivity around it.

4. Expansion options and risks

  • International expansion: the ZAVA acquisition provides a European base, and the company has outlined a 2026 Canada expansion plan.
  • New categories: oral testosterone through Marius, cancer early detection through GRAIL, menopause/perimenopause, and longevity expand the surface area.
  • Regulation: compounded GLP-1, telehealth prescribing rules, DEA/HHS controlled-substance flexibility, and state-level telehealth rules remain ongoing checks.
  • Competition: against Ro/Roman and others, customer acquisition cost, trust, pricing, and medication supply stability are key.

5. My checklist

Interpretation: I would track subscribers, personalized-plan mix, GLP-1 revenue quality, gross margin, adjusted EBITDA margin, FDA/DEA rule changes, and international expansion costs together. For the thesis to work, HIMS has to prove it is a recurring healthcare operating system, not just a GLP-1 event stock.

Sources

Naver original